Gufic Bio Standalone December 2021 Net Sales at Rs 172.07 crore, up 19.15% Y-o-Y
NULL11-02-2022
GUFIC BIOSCIENCES LTD. - 509079 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, audio call recording of the Earnings Conference Call held on February 10, 2022 at 4:30 p.m. has been uploaded on the Company's website and can be accessed through the link: http://gufic.com/Notice/AUDIORECORDING_10022022.mp3 Written transcript of the same will be submitted in due course. Kindly take the same on record.10-02-2022
Q3FY22 Quarterly Result Announced for Gufic BioSciences Ltd.
Pharmaceuticals company Gufic BioSciences declares Q3FY22 result: The Non-CoVID portfolio of Criticare Group has shown strong growth fueled by Penem Portfolio (Doripenem, Ertapenem, Meropenem, Imipenem & Faropenem) and the Anti Fungal portfolio (Micafungin, Caspofungin & Anidulafungin) Core Infertility Portfolio has nearly doubled. We have seen healthy growth in this portfolio even when compared to the pre-pandemic period due to certain changes in strategies Herbal Products – Launched a new range of Multi-Vitamins which has led to high growth in this segment Spark Division – A new product portfolio will be launched under the Cardiac Diabetic Management in Q2 FY23 Stellar – The division was launched last year, and we are seeing good traction in this segment. We plan to launch 6 to 8 new products in the coming six months Aesthaderm – Stunnox has registered strong growth and continues to see positive trends. This would be one of the pillar brands going ahead Result PDF10-02-2022
GUFIC BIOSCIENCES LTD. - 509079 - Board Meeting Outcome for Outcome Of The Board Meeting
Pursuant to the provisions of Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we would like to inform that the Board of Directors at their meeting held on February 09, 2022 i.e., today, inter alia considered and approved the following matters: 1. Un-audited Financial Results of the Company for the quarter and nine months ended December 31, 2021; 2. Formation / Incorporation of a Wholly Owned Subsidiary of the Company in United Kingdom (UK) and Ireland. The incorporation of the abovementioned wholly owned subsidiaries in UK and Ireland will expand the business opportunities of the Company and get several product registrations in its name in whole of UK and Europe, respectively. The Board of Directors meeting commenced at 04:00 p.m. and concluded at 7.00 p.m. Kindly take the same on your record.09-02-2022
GUFIC BIOSCIENCES LTD. - 509079 - Results-Un-Audited Financial Results For The Quarter And Nine Months Ended December 31, 2021
Pursuant to the provisions of Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we would like to inform that the Board of Directors at their meeting held on February 09, 2022 i.e., today, inter alia considered and approved the following matters: 1. Un-audited Financial Results of the Company for the quarter and nine months ended December 31, 2021; In terms of provisions of Regulation 33 of the Listing Regulations, we enclose herewith the following : i. Un-Audited Standalone Financial Results for the quarter and nine months ended December 31, 2021; ii. Limited Review Report issued by the Statutory Auditor of the Company on the Un-Audited Financial Results for the quarter and nine months ended December 31, 2021; iii. Investors' Presentation The Board of Directors meeting commenced at 04:00 p.m. and concluded at 7.00 p.m. Kindly take the same on your record.09-02-2022
GUFIC BIOSCIENCES LTD. - 509079 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 read with Part A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please be informed that the Company will host an Earnings Conference Call for Investors/Analysts on Thursday, February 10, 2022, at 16:30 hours (IST), during which officials of the Company will discuss the business background/prospects and financial performance of the Company and take questions. Enclosed herewith the instructions for joining the meeting. Kindly take the same on record.07-02-2022
GUFIC BIOSCIENCES LTD. - 509079 - Board Meeting Intimation for Approval Of Un-Audited Financial Results For The Quarter And Nine Months Ended December 31, 2021.
GUFIC BIOSCIENCES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2022 ,inter alia, to consider and approve the Un-Audited Financial Results of the Company for the quarter and nine months ended December 31, 2021. Further in continuation to our disclosure on Closure of Trading Window dated December 29, 2021 and pursuant to the Company's Code of Conduct framed in accordance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, as amended, the trading window in respect of dealing in the Equity Shares of the Company for all the Directors and designated (specified) employees of the Company, shall continue to remain closed until 48 hours after declaration of the Un-Audited Financial Results of the Company for the quarter and nine months ended December 31, 2021. Kindly take the same on your record.02-02-2022
GUFIC BIOSCIENCES LTD. - 509079 - Disclosure of Voting results of Postal Ballot (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Gufic Biosciences Ltd has informed BSE regarding the details of Voting results of Postal Ballot, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here21-01-2022
GUFIC BIOSCIENCES LTD. - 509079 - Result Of Postal Ballot And Scrutinizer Report
Pursuant to the above captioned subject, we enclose herewith the results of voting of the Members of the Company, conducted by way of postal ballot (remote e-voting) as per the format prescribed under the provisions of Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Also enclosed is the copy of the Scrutinizers'' Report submitted by the Scrutinizer on postal ballot and the same is uploaded on the website of the Company www.gufic.com. Please note that the Ordinary Resolution for Re-appointment of Mr. Pankaj J. Gandhi (DIN:00001858) as a Whole Time Director of the Company has been passed with requisite majority. Kindly take the same on your record.21-01-2022
GUFIC BIOSCIENCES LTD. - 509079 - Shareholding for the Period Ended December 31, 2021
Gufic Biosciences Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2021. For more details, kindly Click here20-01-2022